Calithera Biosciences EBITDA 2013-2022 | CALA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Calithera Biosciences ebitda from 2013 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Calithera Biosciences ebitda from 2013 to 2022. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.

Related Stocks
Company Name	Market Cap
Chugai Pharmaceutical (CHGCY)	$81.7B
Zoetis (ZTS)	$66.3B
Daiichi Sankyo, - (DSNKY)	$46.4B
Takeda Pharmaceutical (TAK)	$43.3B
BeOne Medicines - (ONC)	$32.9B
Sandoz Group AG (SDZNY)	$25.9B
Summit Therapeutics (SMMT)	$19.8B
Merck (MKKGY)	$16.5B
Shionogi (SGIOY)	$14.3B
Neurocrine Biosciences (NBIX)	$13.5B
United Therapeutics (UTHR)	$12.7B
Orion OYJ (ORINY)	$11.5B
IPSEN (IPSEY)	$10.8B
Stevanato Group S.p.A (STVN)	$7.6B
Grifols, S.A (GRFS)	$7.5B
Corcept Therapeutics (CORT)	$7.4B
Ionis Pharmaceuticals (IONS)	$6.9B
Madrigal Pharmaceuticals (MDGL)	$6.4B
Hikma Pharmaceuticals Plc (HKMPF)	$5.9B
Ono Pharmaceutical (OPHLF)	$5.2B
Soleno Therapeutics (SLNO)	$4.3B
Hypermarcas (HYPMY)	$3.1B
Crinetics Pharmaceuticals (CRNX)	$2.7B
Catalyst Pharmaceuticals (CPRX)	$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.5B
NewAmsterdam Pharma (NAMS)	$2.5B
Centessa Pharmaceuticals (CNTA)	$2.2B
Ocular Therapeutix (OCUL)	$1.9B
Endo (NDOI)	$1.8B
ARS Pharmaceuticals (SPRY)	$1.8B